Science Explorer Back to mapMap
Discussion
Institution · Epic Sciences (United States)

Most cited papers from Epic Sciences (United States)

Epic Sciences (United States)

What are the most cited papers from Epic Sciences (United States)?

The most cited paper from Epic Sciences (United States) is "Cutting Edge: The Conversion of Arginine to Citrulline Allows for a High-Affinity Peptide Interaction with the Rheumatoid Arthritis-Associated HLA-DRB1*0401 MHC Class II Molecule" (Jonathan A. Hill, Scott Southwood, Alessandro Sette et al., 2003), with 716 citations. Next come "Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires" (670) and "Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer" (647).

Showing 50 of 60 papers. Every paper with more than 27 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Cutting Edge: The Conversion of Arginine to Citrulline Allows for a High-Affinity Peptide Interaction with the Rheumatoid Arthritis-Associated HLA-DRB1*0401 MHC Class II Molecule Jonathan A. Hill, Scott Southwood, Alessandro Sette et al. · The Journal of Immunology Jul 2003 716
2 Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires Scott Southwood, John Sidney, Akihiro Kondo et al. · The Journal of Immunology Apr 1998 670
3 Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer Howard I. Scher, David M. Lu, Nicole A. Schreiber et al. · JAMA Oncology Open access 4 Jun 2016 647
4 Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study Andrew J. Armstrong et al. · Journal of Clinical Oncology Open access 13 Mar 2019 368
5 Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations Fatima H. Karzai et al. · Journal for ImmunoTherapy of Cancer Open access Dec 2018 314
6 Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer Karen A. Autio, Robert Dreicer, Justine Anderson et al. · JAMA Oncology Open access 6 Jul 2018 268
7 Induction of AIDS Virus-Specific CTL Activity in Fresh, Unstimulated Peripheral Blood Lymphocytes from Rhesus Macaques Vaccinated with a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen Todd M. Allen, Thorsten U. Vogel, DEBORAH HEYDENBURG FULLER et al. · The Journal of Immunology May 2000 251
8 Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer Howard I. Scher, Ryon P. Graf, Nicole A. Schreiber et al. · JAMA Oncology Open access 28 Jun 2018 243
9 Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer Loredana Puca et al. · Science Translational Medicine Open access 20 Mar 2019 217
10 Emissions from Ships with respect to Their Effects on Clouds Peter V. Hobbs, Timothy J. Garrett, Ronald J. Ferek et al. · Journal of the Atmospheric Sciences Open access Aug 2000 205
11 Linear PADRE T Helper Epitope and Carbohydrate B Cell Epitope Conjugates Induce Specific High Titer IgG Antibody Responses Jeff Alexander, Marie‐France del Guercio, Ajesh Maewal et al. · The Journal of Immunology Feb 2000 192
12 Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer Howard I. Scher, Ryon P. Graf, Nicole A. Schreiber et al. · European Urology Open access 12 Dec 2016 186
13 Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer Karim Boudadi et al. · Oncotarget Open access 18 Jun 2018 158
14 The optimization of helper T lymphocyte (HTL) function in vaccine development Jeff Alexander, John D. Fikes, Stephen L. Hoffman et al. · Immunologic Research Oct 1998 149
15 Who Validates the Validators? Aligning LLM-Assisted Evaluation of LLM Outputs with Human Preferences Shreya Shankar, J.D. Zamfirescu-Pereira, Bjoern Hartmann et al. Conference paperOpen access 11 Oct 2024 143
16 Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential Jelena Knežević, Adam D. Pfefferle, Ivana M. Petrovic et al. · Oncogene Open access 9 Mar 2015 142
17 Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer Howard I. Scher, Ryon P. Graf, Nicole A. Schreiber et al. · Cancer Research Open access 17 Aug 2017 137
18 The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer Himisha Beltran, Adam Jendrisak, Mark Andrew Landers et al. · Clinical Cancer Research Open access 15 Dec 2015 134
19 Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization Shannon L. Werner, Ryon P. Graf, Mark Andrew Landers et al. · Journal of Circulating Biomarkers Open access 30 Jan 2015 127
20 Identification of HLA-A3 and -B7-Restricted CTL Response to Hepatitis C Virus in Patients with Acute and Chronic Hepatitis C Kyong‐Mi Chang, Norbert H. Gruener, Scott Southwood et al. · The Journal of Immunology 1999 117
21 Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients Archana Anantharaman, Terence W. Friedlander, David M. Lu et al. · BMC Cancer Open access 21 Sep 2016 105
22 The Impact of Ship-Produced Aerosols on the Microstructure and Albedo of Warm Marine Stratocumulus Clouds: A Test of MAST Hypotheses 1i and 1ii P. A. Durkee et al. · Journal of the Atmospheric Sciences Open access Aug 2000 104
23 High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis Jorge J. Nieva, Marco Wendel, Madelyn S. Luttgen et al. · Physical Biology Open access Feb 2012 102
24 Just eat it: A review of CD47 and SIRP-α antagonism Bryan T. Oronsky, Corey Carter, Tony Reid et al. · Seminars in Oncology Apr 2020 90
25 PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients Elizabeth A. Punnoose et al. · British Journal of Cancer Open access 17 Sep 2015 90
26 Cellular Immune Responses to the Hepatitis B Virus Polymerase Eishiro Mizukoshi, John Sidney, Brian D. Livingston et al. · The Journal of Immunology Open access Nov 2004 89
27 HLA-Independent Heterogeneity of CD8+ T Cell Responses to MAGE-3, Melan-A/MART-1, gp100, Tyrosinase, MC1R, and TRP-2 in Vaccine-Treated Melanoma Patients Sandra R. Reynolds, Esteban Celis, Alessandro Sette et al. · The Journal of Immunology Dec 1998 87
28 Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer Andrew J. Armstrong et al. · JCO Precision Oncology Open access 28 Oct 2020 82
29 Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer Paymaneh D. Malihi, Ryon P. Graf, Ángel Rodríguez et al. · Clinical Cancer Research Open access 27 Apr 2020 78
30 Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer Ryon P. Graf, Melanie A. Hullings, Ethan S. Barnett et al. · European Urology Open access 21 Oct 2019 78
31 SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy Vincenza Conteduca, Sheng‐Yu Ku, Loredana Puca et al. · Molecular Cancer Therapeutics Open access 3 Mar 2020 74
32 Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial Eugene Shenderov, Karim Boudadi, Wei Fu et al. · The Prostate Open access 26 Feb 2021 73
33 Overcoming T Cell Tolerance to the Hepatitis B Virus Surface Antigen in Hepatitis B Virus-Transgenic Mice Alessandro Sette, Carla Oseroff, John Sidney et al. · The Journal of Immunology 2001 73
34 Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival Daniel J. Boffa, Ryon P. Graf, Michelle C. Salazar et al. · Cancer Epidemiology Biomarkers & Prevention Open access 26 Apr 2017 72
35 The Caspase Selective Inhibitor EP1013 Augments Human Islet Graft Function and Longevity in Marginal Mass Islet Transplantation in Mice Juliet A. Emamaullee, Joy Davis, Rena L. Pawlick et al. · Diabetes Open access 21 Mar 2008 67
36 Phenotypic diversity of circulating tumour cells in patients with metastatic castration‐resistant prostate cancer Andrew S. McDaniel, Roberta Ferraldeschi, Rachel Krupa et al. · British Journal of Urology Open access 18 Aug 2016 66
37 Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: Scientific Opportunities and Logistics for Cancer Clinical Trial Incorporation Lori E. Lowes, Scott Victor Bratman, Ryan Vance Dittamore et al. · International Journal of Molecular Sciences Open access 8 Sep 2016 66
38 Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis Stephanie B. Greene, Angel Ernesto Dago, Laura Leitz et al. · PLoS ONE Open access 16 Nov 2016 54
39 Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer Howard I. Scher, Andrew J. Armstrong, Joseph D. Schonhoft et al. · European Journal of Cancer Open access 21 Apr 2021 51
40 Cytokine and chemokine profiles in fibromyalgia, rheumatoid arthritis and systemic lupus erythematosus: a potentially useful tool in differential diagnosis Daniel J. Wallace, Igor M. Gavin, О. В. Карпенко et al. · Rheumatology International Open access 7 Nov 2014 51
41 The HLA Molecules DQA1*0501/B1*0201 and DQA1*0301/B1*0302 Share an Extensive Overlap in Peptide Binding Specificity John Sidney, Marie‐France del Guercio, Scott Southwood et al. · The Journal of Immunology Open access Nov 2002 50
42 Simultaneous Prediction of Binding Capacity for Multiple Molecules of the HLA B44 Supertype John Sidney, Scott Southwood, Valérie Pasquetto et al. · The Journal of Immunology Dec 2003 49
43 Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer Heather J. Chalfin et al. · Clinical Cancer Research Open access Dec 2020 48
44 Collaborating to Compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium Robert L. Grossman et al. · Clinical Pharmacology & Therapeutics Open access 10 Feb 2017 48
45 Minimum Technical Data Elements for Liquid Biopsy Data Submitted to Public Databases Phillip G. Febbo et al. · Clinical Pharmacology & Therapeutics Open access 4 Feb 2020 47
46 Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer Anthony V. Serritella, Daniel Shevrin, Elisabeth I. Heath et al. · Clinical Cancer Research Open access 2 Feb 2022 46
47 Immunization with the HBV core 18–27 epitope elicits CTL responses in humans expressing different HLA-A2 supertype molecules Brian D. Livingston, Claire Crimi, John D. Fikes et al. · Human Immunology Nov 1999 46
48 Morphology-Predicted Large-Scale Transition Number in Circulating Tumor Cells Identifies a Chromosomal Instability Biomarker Associated with Poor Outcome in Castration-Resistant Prostate Cancer Joseph D. Schonhoft, Jimmy L. Zhao, Adam Jendrisak et al. · Cancer Research Open access 19 Aug 2020 42
49 Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-α2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma Mark Ross Middleton, Axel Hauschild, Damien B. Thomson et al. · Annals of Oncology Open access 21 Aug 2007 40
50 Quantification of cellular volume and sub-cellular density fluctuations: comparison of normal peripheral blood cells and circulating tumor cells identified in a breast cancer patient Kevin G. Phillips, Anand R. Kolatkar, Kathleen J. Rees et al. · Frontiers in Oncology Open access 2012 40

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.